Nasopharyngeal Pneumococcal Carriage in Nigeria: a two-site, population-based survey

Sci Rep. 2018 Feb 22;8(1):3509. doi: 10.1038/s41598-018-21837-5.

Abstract

Changes in nasopharyngeal (NP) carriage of vaccine-type (VT) Streptococcus pneumoniae can be used to assess the effectiveness of a pneumococcal conjugate vaccine (PCV10). We conducted a baseline carriage survey in rural (Kumbotso, Kano) and urban (Pakoto, Ogun) Nigeria. In this cross-sectional study, we obtained data on demography, clinical history, risk factors, and took NP swabs for pneumococcal culture. We calculated crude and age-standardised carriage prevalence and used log-binomial regression to assess risk factors for carriage. Among children aged <5 years, 92% (95% CI: 88-95%) and 78% (73-82%), respectively, carried any pneumococcus and 48% and 50%, respectively, carried PCV10 serotypes. In Kumbotso, carriage prevalence was >40% across all ages. The age-standardized prevalence of pneumococcal carriage was 66% in Kumbotso and 40% in Pakoto. The most commonly identified serotypes were 19 F, 6 A and 23 F. Risk factors for carriage were young age, recent rhinorrhoea, cohabitation with ≥2 children aged <5 years, and sharing a bed with ≥2 persons. Pneumococcal carriage prevalence is high in this Nigerian population. Persisting prevalence of VT-carriage in older children and adults suggests that PCV10 introduction in children will not eliminate transmission of vaccine serotypes rapidly. High vaccine coverage will therefore be required to ensure full protection of children.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Male
  • Nasopharyngeal Diseases / epidemiology*
  • Nasopharyngeal Diseases / immunology
  • Nasopharyngeal Diseases / microbiology
  • Nasopharyngeal Diseases / prevention & control
  • Nigeria / epidemiology
  • Pneumococcal Infections / epidemiology*
  • Pneumococcal Infections / immunology
  • Pneumococcal Infections / microbiology
  • Pneumococcal Infections / prevention & control
  • Pneumococcal Vaccines / immunology
  • Pneumococcal Vaccines / therapeutic use*
  • Rural Population
  • Streptococcus pneumoniae / pathogenicity
  • Urban Population
  • Vaccines, Conjugate / therapeutic use*

Substances

  • 10-valent pneumococcal conjugate vaccine
  • Pneumococcal Vaccines
  • Vaccines, Conjugate